Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

• ClinicalTrials.gov Identifier: NCT04919642
• Recruitment Status: Completed
• First Posted: June 9, 2021
• Last Update Posted: April 26, 2024
• Sponsor: TransThera Sciences (Nanjing), Inc.
• Information provided by (Responsible Party): TransThera Sciences (Nanjing), Inc.

Tracking Information

• First Submitted Date: May 27, 2021
• First Posted Date: June 9, 2021
• Last Update Posted Date: April 26, 2024
• Actual Study Start Date: December 7, 2021
• Actual Primary Completion Date: February 28, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 26, 2022)

• Objective Response Rate (ORR) in patients with FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor (Cohort A1) [ Time Frame: Through study completion, an average of 9 months. ]
  The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.
• ORR in patients with FGFR2 fusions who have responded (CR or PR) on at least one previous treatment with an FGFR inhibitor and discontinued due to progressive disease (Cohort A2) [ Time Frame: Through study completion, an average of 9 months. ]
• ORR in patients with FGFR alterations other than FGFR2 fusions (Cohort B) [ Time Frame: Through study completion, an average of 9 months. ]
• ORR in patients without FGFR alterations (wild-type FGFR mutation status) (Cohort C) [ Time Frame: Through study completion, an average of 9 months. ]

Original Primary Outcome Measures (submitted: June 2, 2021)

• Objective Response Rate (ORR) in patients with FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor (Cohort A1) [ Time Frame: Through study completion, an average of 9 months. ]
  The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.
• ORR in patients with FGFR2 fusions who have responded (CR or PR) on at least one previous treatment with an FGFR inhibitor and discontinued due to progressive disease (Cohort A2) [ Time Frame: Through study completion, an average of 9 months. ]

Current Secondary Outcome Measures (submitted: January 26, 2022)

• ORR in all patients with FGFR alterations (Cohorts A and B) [ Time Frame: Through study completion, an average of 9 months. ]
• Progression Free Survival (PFS) (All Cohorts) [ Time Frame: From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
• Disease Control Rate (DCR) (All Cohorts) [ Time Frame: Through study completion, an average of 9 months. ]
  Defined as CR + PR + stable disease (SD)
• Overall Survival (OS) (All Cohorts) [ Time Frame: From first study drug administration until the date of death from any cause, assessed up to 24 months ]
• Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (All Cohorts) [ Time Frame: Up to 30 days from study discontinuation ]
  As assessed per CTCAE version 5.0
• Concentration of TT-00420 at Protocol-Specified Timepoints (All Cohorts) [ Time Frame: From Cycle 1 to Cycle 4, an average of 4 months (each cycle is 28 days) ]

Original Secondary Outcome Measures (submitted: June 2, 2021)

• ORR in patients with FGFR alterations other than FGFR2 fusions (Cohort B) [ Time Frame: Through study completion, an average of 9 months. ]
• ORR in all patients with FGFR alterations (Cohorts A and B) [ Time Frame: Through study completion, an average of 9 months. ]
• ORR in patients without FGFR alterations (wild-type FGFR mutation status) (Cohort C) [ Time Frame: Through study completion, an average of 9 months. ]
• Progression Free Survival (PFS) (All Cohorts) [ Time Frame: From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
• Disease Control Rate (DCR) (All Cohorts) [ Time Frame: Through study completion, an average of 9 months. ]
  Defined as CR + PR + stable disease (SD)
• Overall Survival (OS) (All Cohorts) [ Time Frame: From first study drug administration until the date of death from any cause, assessed up to 24 months ]
• Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (All Cohorts) [ Time Frame: Up to 30 days from study discontinuation ]
  As assessed per CTCAE version 5.0
• Concentration of TT-00420 at Protocol-Specified Timepoints (All Cohorts) [ Time Frame: From Cycle 1 to Cycle 4, an average of 4 months (each cycle is 28 days) ]

Current Other Pre-specified Outcome Measures (submitted: June 2, 2021)

Genetic Alteration Status [ Time Frame: Through study completion, an average of 9 months ]

Evaluation of biomarkers, including but not limited to, FGFR mutation status

• Original Other Pre-specified Outcome Measures: Same as current

Descriptive Information

• Brief Title: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
• Official Title: A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma
• Brief Summary: This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.
• Detailed Description: This is a Phase II, open-label study to evaluate the efficacy and safety of TT00420 in patients with advanced/metastatic and surgically unresectable cholangiocarcinoma (CCA) with 1) FGFR 2 fusions who failed prior FGFR inhibitor treatment, 2) FGFR2 fusions who responded on prior FGFR inhibitor treatment, 3) with other FGFR alterations, or 4) whose tumors do not contain a detectable FGFR alteration.
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Cholangiocarcinoma
• FGFR2 Fusion
• FGFR2 Gene Mutation
• FGFR1 Alteration
• FGFR3 Alteration

Intervention

Drug: TT-00420

TT-00420 tablet, administered orally once daily

Study Arms

• Experimental: Cohort A1
  FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor
  Intervention: Drug: TT-00420
• Experimental: Cohort A2
  FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor and discontinued due to disease progression
  Intervention: Drug: TT-00420
• Experimental: Cohort B
  Other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions
  Intervention: Drug: TT-00420
• Experimental: Cohort C
  Negative for FGFR alterations (FGFR wild-type)
  Intervention: Drug: TT-00420

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: October 25, 2023): 55
• Original Estimated Enrollment (submitted: June 2, 2021): 80
• Actual Study Completion Date: February 28, 2024
• Actual Primary Completion Date: February 28, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. ≥ 18 years of age, at the time of signing informed consent

2. Histologically or cytologically documented advanced/metastatic or surgically unresectable cholangiocarcinoma who have received at least one line of prior systemic chemotherapy. Patients will be assigned to 1 of 4 cohorts:

   • Cohort A1: FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor
   • Cohort A2: FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor
   • Cohort B: other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions
   • Cohort C: negative for FGFR alterations (FGFR wild-type)
3. At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors5
4. Documentation of FGFR gene alteration status
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Adequate organ function confirmed at screening and within 10 days of initiating treatment, as evidenced by:

   • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
   • Hemoglobin (Hgb) ≥ 8 g/dl
   • Platelets (plt) ≥ 75 x 10^9/L
   • aspartate aminotransferase/serum glutamate oxaloacetate transaminase (AST/SGOT) and alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT) ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
   • Total bilirubin ≤ 1.5 x ULN
   • Calculated creatine clearance ≥ 50 mL/min (Cockcroft Gault formula
7. Negative pregnancy test within 72 hours before starting study treatment in all premenopausal women and women < 12 months after the onset of menopause
8. Must agree to take sufficient contraceptive methods to avoid pregnancy (including male and female participants) during the study and until at least 6 months after ceasing study treatment
9. Able to sign informed consent and comply with the protocol

Exclusion Criteria:

1. Women who are pregnant or lactating
2. Women of child-bearing potential (WOCBP) who do not use adequate birth control
3. Patients with untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed (e.g. evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain/CNS metastases) Note: Patients with treated brain metastases that are off corticosteroids and have been clinically stable for 28 days are eligible for enrollment.
4. Patients with a known concurrent malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, carcinoma in situ of the cervix or other noninvasive or indolent malignancy that has previously undergone potentially curative therapy.

5. Patients with the following mood disorders as judged by the Investigator or a psychiatrist:

   • Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia; a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
   • ≥ CTCAE grade 3 anxiety

6. Impaired cardiac function or significant diseases, including but not limited to any of the following:

   • left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)
   • Congenital long QT syndrome
   • QTcF ≥ 480 msec on screening ECG
   • Unstable angina pectoris ≤ 3 months prior to starting study drug
   • Acute myocardial infarction ≤ 3 months prior to starting study drug
7. Patients with uncontrolled hypertension (defined as blood pressure of ≥ 150 mmHg systolic and/or ≥ 90 mmHg diastolic at Screening)

8. Patients with:

   • unresolved diarrhea ≥ CTCAE grade 2, or
   • impairment of gastrointestinal (GI) function, or
   • GI disease that may significantly alter the absorption of TT-00420.
9. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. uncontrolled hypertriglyceridemia [triglycerides > 500 mg/dL], or active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
10. Patients who have received chemotherapy, targeted therapy, or immunotherapy ≤ 5 half-lives or 3 weeks, whichever is shorter, (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug
11. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy
12. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy
13. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants
14. Patients who are currently receiving treatment with strong CYP3A inhibitors or inducers, or sensitive substrates of CYP3A4 ≤ 2 weeks prior to starting study drug.
15. Patients who are using a proton pump inhibitor within 4 days prior to the start of study therapy or a histamine-2 blocker within 2 days prior to the start of study therapy.
16. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion and Sponsor approval)
17. Evidence of active infection with Hepatitis B or Hepatitis C that is not adequately controlled. For patients with known prior history of Hepatitis B or Hepatitis C, enrollment may be allowed per investigator's discretion and Sponsor approval.
18. Inability to swallow or tolerate oral medication
19. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT04919642
• Other Study ID Numbers: TT420C1206
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: TransThera Sciences (Nanjing), Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: TransThera Sciences (Nanjing), Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Milind Javle, MD; M.D. Anderson Cancer Center

• PRS Account: TransThera Sciences (Nanjing), Inc.
• Verification Date: December 2023